Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020

Figures

• 

  Figure 1. Registers included and their follow‐up period.

• 

  Figure 2. Cohort creation flow chart. HF, heart failure; NorPD, Norwegian Prescription Database; NPR, Norwegian Patient Registry.

• 

  Figure 3. Cumulative frequency of patients who claimed at least one prescription of BB, RASi, and MRA within the first year following diagnosis (censored for death) for the (A) total patient cohort and (B) drug‐naïve patients. BB, beta‐blocker; MRA, mineralocorticoid receptor antagonist; RASi, renin–angiotensin system inhibitor.

• 

  Figure 4. Proportion of adherent patients 1 year after therapy initiation, defined as PDC ≥ 80%. BB, beta‐blocker; MRA, mineralocorticoid receptor antagonist; PDC, proportion of days covered; RASi, renin–angiotensin system inhibitor. The asterisk (*) shows the results when using the modified PDC adherence measure with the fill frequency method.

• 

  Figure 5. Long‐term persistence with RASi, BB, and MRA. The proportion of patients who were on treatment on each day, censored for death. BB, beta‐blocker; MRA, mineralocorticoid receptor antagonist; RASi, renin–angiotensin system inhibitor. (A) Main analysis, 30 days grace period. (B) Main analysis, 90 days grace period. (C) Fill frequency method, 30 days grace period. (D) Fill frequency method, 90 days grace period.

• 

  Figure 6. Long‐term persistence with ARB, ACEI, and ARNI. The proportion of patients who were on treatment on each day, censored for death. ACEI, angiotensin‐converting enzyme inhibitor; ARB; angiotensin II receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor. (A) Main analysis, 30 days grace period. (B) Main analysis, 90 days grace period. (C) Fill frequency method, 30 days grace period. (D) Fill frequency method, 90 days grace period.